INTRODUCTION
Neutrophils, the most abundant white blood cells, form the first line of defense against pathogenic insults (1) . Upon their mobilization from the bone marrow, neutrophils circulate in the blood and can rapidly migrate to peripheral tissues in response to infection or inflammation. The extravasation process is a cascade of low-and high-affinity adhesive interactions between migrating neutrophils and the vascular endothelium of blood vessels, ultimately including those that feed infected or inflamed tissues; extravasation involves a series of distinct neutrophil functions, including tethering and rolling, activation, firm adhesion to vascular endothelial cells, intraluminal crawling, and transmigration into tissues (1, 2) . Firm adhesion and crawling are largely dependent on interactions between leukocyte b 2 integrins (heterodimeric leukocyte adhesion molecules that comprise a distinct CD11 protein subunit and a common CD18 protein subunit) and endothelial counterreceptors, such as the intercellular adhesion molecule-1 (ICAM-1) and ICAM-2. The LFA-1 b 2 integrin (CD11a/CD18), a leukocyte adhesion molecule on the surface of neutrophils, functions in firm adhesion, which is essential to the subsequent extravasation of neutrophils to peripheral tissues (1, 2).
Although they are important in innate immune defense, neutrophils can also cause tissue damage if their activity is not properly regulated. In this regard, neutrophil homeostasis entails regulation of extravasation, tight control of granulopoiesis (synthesis of granulocyte cells, including neutrophils), release of mature neutrophils from the bone marrow, and clearance of apoptotic neutrophils (3) (4) (5) . Stark and colleagues proposed a feedback loop mechanism that coordinates the peripheral clearance of apoptotic neutrophils that have transmigrated into tissues with neutrophil production and release from the bone marrow (6) . According to this neutrophil rheostat ("neutrostat") model, the phagocytosis of transmigrated apoptotic neutrophils by tissue macrophages and dendritic cells at the site of infection or inflammation suppresses their expression of the proinflammatory cytokine interleukin-23 (IL-23); this leads to decreased production of the proinflammatory cytokine IL-17 and of granulocyte colony-stimulating factor (G-CSF) by fibroblasts and other cells and, ultimately, downregulation of granulopoiesis (6) . This regulatory circuit is disrupted in leukocyte adhesion molecule-deficient mice, which results in unrestrained tissue expression of IL-17 (6) . However, this homeostatic breakdown has yet to be linked to an IL-17-driven disorder in animal disease models or in humans. Moreover, it is uncertain whether IL-17 is excessively elevated in humans with leukocyte adhesion deficiency (LAD) or contributes to any of the clinical manifestations of this disorder.
LAD-I is an autosomal recessive immunodeficiency caused by mutations in the CD18-encoding ITGB2 gene that result in defective neutrophil adhesion and transmigration. Affected individuals display neutrophilia, suffer from recurrent infections, and invariably develop early-onset generalized aggressive periodontitis featuring severe periodontal bone loss and premature tooth loss, which historically has been attributed to defective innate immune surveillance of the periodontal infection (7) (8) (9) (10) (11) (12) (13) . Successful bone marrow transplantation in LAD-I patients reverses the periodontal disease phenotype (14) . Mice deficient in CD18 or CD11a exhibit neutrophilia and defective neutrophil adhesion and extravasation (6, 15) and are thus useful models to study mechanisms of LAD-I-associated pathology.
Here, we report on clinical findings in LAD-I patients and mechanistic studies in mouse models that show that defective neutrophil recruitment is associated with dysregulated local overproduction of IL-17, and it is this cytokine excess that drives inflammatory periodontal bone loss. These results suggest promising treatment options for intractable LAD-I periodontitis.
RESULTS
Human LAD-I periodontitis exhibits an IL-17-dominated gene expression signature To investigate the mechanistic basis of LAD-I periodontitis, we clinically evaluated and followed a cohort of patients diagnosed with LAD-I based on the identification of mutations in the CD18-encoding ITGB2 gene and diminished CD18 expression on peripheral neutrophils (table S1), as well as history of recurrent infections since childhood. Periodontitis with severe loss of tooth-supporting connective tissue and bone was clinically diagnosed in all patients in our LAD-I cohort ( Fig. 1A and fig. S1 ). The severity of periodontal tissue destruction [clinical attachment loss (CAL); the distance from the cemento-enamel junction to the base of the periodontal pocket, measured in millimeters] in LAD-I patients (ages 11 to 13 years) inversely correlated with the remaining expression of CD18 on their peripheral neutrophils (Fig. 1B) . This observation suggests a direct link between the patients' defective neutrophil phenotype and severity of LAD-I periodontitis.
LAD-I periodontitis has been historically attributed to a lack of neutrophil innate immune surveillance (ostensibly rendering the patients susceptible to periodontal infections), although the condition has proven unresponsive to antibiotics or mechanical removal of tooth-associated bacterial biofilm (8) . We observed progressive periodontal disease in all patients evaluated, despite prophylactic antibiotic use since infancy and access to dental care. Gram staining of extracted teeth and surrounding tissues from LAD-I patients suggested profound microbial colonization of tooth surfaces but not of underlying diseased gingival tissue (Fig. 1C) , consistent with the absence of a raging infection within the gingiva. Moreover, quantification of bacterial counts in gingival tissue sections from LAD-I patients and healthy controls, using a real-time polymerase chain reaction (PCR) to measure expression of the 16S ribosomal RNA (rRNA) gene, revealed that the bacterial load within the tissue of LAD-I patients was comparable to (if not less than) that of healthy controls ( fig. S2 ). The diseased gingival tissue, however, harbored immunopathological lesions featuring a dense inflammatory infiltrate (Fig. 1D ) composed primarily of lymphocytes, whereas neutrophils were confined within blood vessels (Fig. 1E ). These data suggested that LAD-I periodontitis likely does not result from an unusual tissue-invasive periodontal infection but rather could represent an immunopathological entity, potentially involving mechanism(s) distinct from the slowly progressive chronic or adult-type periodontitis (16) .
To investigate the underlying immunopathological process, we first compared the periodontal cytokine and chemokine gene expression profiles of LAD-I patients with those of systemically healthy patients with severe chronic periodontitis or with gingivitis (that is, periodontal inflammation without bone loss). We detected a marked up-regulation of IL-17A expression in LAD-I periodontitis compared to both gingivitis and periodontitis ( Fig. 2A) . Cytokines linked to the induction and amplification of IL-17A expression, such as IL-1b, IL-6, and IL-23 (17) , were readily expressed in LAD-I periodontitis, although only IL-6 and IL-23p19 were significantly elevated relative to both gingivitis and periodontitis ( Fig. 2A) . Although IL-12p40 was not up-regulated in LAD-I periodontitis, it was detected at concentrations comparable to those expressed in gingivitis and periodontitis. Consistent with the high levels of IL-17A expression, IL-17A-dependent cytokines or chemokines linked to neutrophil granulopoiesis or recruitment, such as G-CSF, CXCL2, and CXCL5, also displayed significant up-regulation in LAD-I periodontitis ( Fig. 2A) . High production of granulopoiesis factors and chemokines was also observed in the local inflammatory exudate bathing the space between the teeth and the free gingiva (gingival crevicular fluid) of LAD-I patients (Fig. 2B) .
Human LAD-I periodontitis is characterized by an abundance of IL-17-expressing cells Consistent with the high levels of IL-17A mRNA expression in LAD-I periodontitis ( Fig. 2A) , immunohistochemical analysis revealed the presence of abundant IL-17-positive cells throughout the inflammatory lesion (Fig. 2C) . IL-17-positive cells were seen predominantly among CD3
+ cell-rich regions (Fig. 2D ). Flow cytometry of mononuclear cells isolated from oral biopsies of LAD-I patients demonstrated considerably higher numbers of IL-17-producing cells compared to healthy control subjects (Fig. 2E) . Characterization of the IL-17-producing cells revealed predominantly CD3 + IL-17 producers (Fig. 2F ), specifically within the CD3 (Fig. 2G ). This T cell population is presumed to be CD4 + , although we were unable to directly stain for CD4 likely because of its down-regulation upon activation (18) . CD3
− IL-17 producers were also present albeit at a lower frequency (Fig. 2F) .
In contrast to oral mucosal areas, blood plasma from LAD-I patients contained little or no IL-23 or IL-17 (Fig. 3A) , and the percentages of IL-17-secreting blood mononuclear cells were similar between LAD-I patients and healthy subjects (Fig. 3B ). These data reveal that the elevated expression of IL-17 in LAD-I is compartmentalized rather than systemic. In contrast, IL-17-induced granulopoiesis factors and chemokines were readily detected in blood plasma of LAD-I patients (Fig. 3A) , correlating with significant neutrophilia relative to healthy subjects (Fig. 3A, inset) .
In summary, our clinical findings demonstrate that LAD-I periodontitis prominently includes aberrant expression of IL-17, consistent with the dysregulation of the IL-23-IL-17 axis previously observed in mouse models of LAD-I (6). To address whether IL-17 drives periodontitis in LAD-I patients would require an intervention study, which could not be performed at present in human subjects. Therefore, we sought evidence for a causal link between IL-17 and LAD-I periodontitis using preclinical models.
Mice with defective neutrophil adhesion or recruitment mirror the IL-17-dominated signature of LAD-I periodontitis Similar to LAD-I patients, mice deficient in CD11a [LFA-1 knockout mice (LFA-1 KO )] experience spontaneous severe periodontal bone loss early in life. However, the periodontal cytokine profile and underlying pathophysiological mechanism underlying bone loss were not previously assessed (19) . We found that 18-week-old LFA-1 KO mice expressed significantly higher levels of IL-23 and IL-17A mRNA + T cells, yet in mice, the predominant T cell source was gd T cells rather than CD4 + T cells (Fig. 4E ). We also identified a significant population of CD45 + CD3
− cells that produced IL-17 ( Fig. 4E ). Further characterization of this population indicated that they were predominantly innate lymphoid cells (CD45 (20) . Consistent with the elevated IL-17, LFA-1 KO mice also showed higher expression of IL-17-dependent genes encoding IL-6, G-CSF, and chemokines (Fig. 4A ). Tumor necrosis factor (TNF), IL-1b, and interferon-g (IFN-g) were also detected in the periodontal tissue of LFA-1 KO mice, but their expression was not as pronounced as that for IL-17 and IL-23 (Fig. 4 , A and B). Consistent with a preferential dysregulation of IL-23 production, the mRNA expression of the IL-12p35 subunit (which is unique to IL-12) was not up-regulated in the periodontal tissue of LFA-1 KO mice, whereas the IL-12-and IL-23-shared p40 subunit as well as IL23p19 were elevated relative to wild-type mice (Fig. 4A ).
Mice deficient in the chemokine receptor CXCR2 (CXCR2 KO ), which fail to recruit neutrophils to the periodontal tissue (21) , displayed a cytokine expression profile and bone loss similar to LFA-1 KO mice (Fig. 4 , A to C), suggesting that defective neutrophil recruitment rather than defective neutrophil adhesion per se causes these abnormalities. Together, these data show that LFA-1 KO and CXCR2 KO mice share the periodontal phenotype of LAD-I patients in terms of early-onset severe bone loss associated with defective neutrophil recruitment and local elevation of IL-17.
IL-23 or IL-17 is required for bone loss and increased bacterial burden in mouse LAD-I periodontitis
To determine whether IL-23 or IL-17 is causally linked to LAD-I periodontitis, we performed intervention experiments in LFA-1 KO mice, which were validated as a model of LAD-I periodontitis (Fig. 4) . LFA-1 KO mice were treated locally in the gingiva with either an anti-IL-17A monoclonal antibody (mAb), an anti-IL-23p19 polyclonal antibody, or control antibodies [immunoglobulin G2a (IgG2a) or nonimmune IgG, respectively] (three times weekly from the age of 4 to 18 weeks). LFA-1 KO mice treated with either anti-IL-17A or anti-IL-23p19 were protected from bone loss and resembled the wild-type mouse phenotype, whereas untreated or control antibody-treated LFA-1 KO mice displayed progressive disease (Fig. 5A ). The antibody-mediated inhibition of bone loss correlated with significantly decreased expression of receptor activator of nuclear factor kB ligand (RANKL), a key osteoclastogenic factor, and other proinflammatory cytokines in the periodontal tissue (Fig. 5B) . Moreover, the expression of IL-17 was diminished by anti-IL-23p19 treatment (Fig. 5B) (Fig. 4E) , the reduction of CD3 + T cells by anti-IL-17 could explain, at least in part, why anti-IL-17 treatment also suppressed IL-17 mRNA expression (Fig. 5B) .
LFA-1 KO mice also exhibited a higher periodontal bacterial load than did wild-type controls (Fig. 5D) , suggestive of dysbiosis (similarly, the tooth-associated periodontal microbiota of LAD-I patients exhibited higher total bacterial counts in comparison with age-matched healthy controls; fig. S3 ). Anti-IL-17 or anti-IL-23p19 antibody treatment caused a reduction in the numbers of cultivable anaerobic bacteria (Fig. 5D, left) and in total periodontal bacterial counts as determined by 16S rRNA real-time PCR (Fig. 5D,  right) . The combined anti-inflammatory and antimicrobial effects of anti-IL-23 or anti-IL-17 are consistent with the notion that IL-17-driven periodontal inflammation fosters bacterial growth, presumably through the generation of tissue breakdown products used as nutrients by the bacteria (22, 23) . These data also suggest that the elevated bacterial burden in untreated LFA-1 KO mice (relative to wild-type controls) may not necessarily or exclusively result from impaired neutrophil surveillance of the periodontal tissue; rather, higher bacterial burden could represent the consequence of increased inflammation. Together, the data in Figs. 4 and 5 suggest that, in the absence of normal neutrophil recruitment, IL-23 and IL-17 are up-regulated in the periodontal tissue and cause bone loss associated with increased bacterial burden.
DISCUSSION
Our analyses of the periodontal tissue from LAD-I patients and relevant animal models collectively demonstrate a primary role for IL-17 in the oral pathology of LAD-I. Our intervention studies in mice exhibiting the LAD-I periodontal phenotype demonstrate that the IL-23-IL-17 axis drives dysbiosis and inflammatory bone loss, a finding with obvious translational implications for the treatment of intractable human LAD-I periodontitis. Our findings not only confer biological relevance to the neutrostat concept established in mice (6) but also provide a human (and animal) disease correlate of this mechanism. Periodontitis was a highly relevant condition on which to test the biological importance of the neutrostat mechanism because of its particular mucosal environment (24) can potentially unleash unregulated production of IL-23 and, hence, local overexpression of IL-17, a notion that was substantiated by our data.
Our findings challenge the traditional concept that LAD-associated periodontitis is mainly attributed to impaired neutrophil surveillance of infection. Because continuous prophylactic antibiotic treatment of LAD-I patients and mechanical removal of tooth-associated microbial biofilm have not been successful in the treatment and prevention of LAD-I periodontitis (8, 25, 26) , there is an urgent need for alternative therapies for this condition. In this regard, IL-17-targeting regimens are promising candidates according to the data presented herein. In addition, our demonstration that defective neutrophil recruitment can lead to IL-17-dependent immunopathology may shed light on the understanding of other diseases associated with LAD-I, such as colitis (27) . shown; results were normalized to those of GAPDH mRNA and are presented as fold induction relative to the mRNA transcript levels of untreated WT controls, which were assigned an average value of 1. (D) Quantification of cultivatable oral anaerobic bacteria (left) and determination of total bacterial burden in the periodontal tissue of the indicated mouse groups by real-time PCR analysis of 16S rRNA gene expression (right). Data were pooled from two independent experiments with three mice per group in each experiment (that is, a total of six mice per group). In (A) (left) and (D), each symbol represents an individual mouse, and small horizontal lines indicate the means. In (A) (right) to (C), data are means ± SEM (n = 6 mice per group). *P < 0.05; **P < 0.01 compared with untreated WT control (one-way ANOVA).
↙ P < 0.05; ↙↙ P < 0.01 compared to untreated LFA-1 KO (one-way ANOVA). CFU, colony-forming units.
The dysbiosis developed in LFA-1 KO mice was reversible by anti-IL-17 treatment, suggesting that the condition was driven by IL-17-dependent inflammation (22, 23) rather than by defective immune surveillance caused by the lack of neutrophils. In this regard, patients with chronic granulomatous disease (CGD) who have defective neutrophil-driven oxygen-dependent bactericidal activity and suffer from recurrent or persistent infections (such as pneumonia and skin abscesses) are not susceptible to periodontitis, in contrast to LAD patients (9) . This observation suggests that defective immune surveillance by neutrophils may not be a dominant factor in susceptibility to periodontitis, possibly because neutrophils could be compensated for, in that regard, by other phagocytic cells such as macrophages. In stark contrast, the extravasation competence of neutrophils appears to be essential for periodontal tissue homeostasis. Our recent demonstration that neutrophils migrate normally to the periodontal tissue in the absence of bacterial colonization (that is, in germ-free mice) (21) further suggests that neutrophil recruitment may serve homeostatic functions that are not necessarily related to infection control.
Our microbiological findings from human patients further support the notion that LAD-I periodontitis is unlikely to result from an unusual tissue-invasive periodontal infection. This, however, does not exclude the involvement of the tooth-associated microbiota in the pathogenic process. The local microbiota can act as the initial stimulus to unleash the disinhibited IL-23-IL-17 axis. Note that bacteria do not have to invade the periodontal tissue to stimulate inflammatory cells. This is because released bacterial products capable of activating inflammatory cells (for example, lipopolysaccharide) can readily penetrate through the gingival junctional epithelium, which is highly porous because the cells are interconnected by only a few desmosomes and occasional gap junctions (28) .
To strengthen the notion that defective neutrophil recruitment underlies IL-17-mediated pathology in LAD-I, we performed studies in two distinct models with neutrophil defects: LFA-1 KO and CXCR2 KO mice. The chemokine receptor CXCR2 is essential for tissue recruitment of neutrophils (29, 30) , consistent with the observation that the extravascular sites in the periodontal tissue of CXCR2 KO mice are nearly completely void of neutrophils (21) . The LFA-1 integrin is crucial for the recruitment of neutrophils to peripheral tissues (15, 31, 32) but less important for other leukocytes, which use different or additional adhesion molecules [for example, very late antigen-4 (VLA-4)] for this function (33) (34) (35) (36) (37) . This explains why the inflammatory infiltrates in the periodontium of LAD-I patients are specifically devoid of neutrophils, which are confined in vessels, whereas lymphocytes (including plasma cells) and other cells of hematopoietic origin can be found in abundance within the periodontium.
We found increased numbers of plasma cells in the lesions of LAD-I periodontitis; whether their abundance can be attributed to the overexpression of IL-17 is uncertain. In this respect, IL-17 has been shown to enhance the survival and proliferation of human B cells and their differentiation into plasma cells (38) . Given that B cells and plasma cells constitute a major source of RANKL in the bone-resorptive lesions of chronic periodontitis (39) , the abundance of plasma cells in LAD-I periodontitis might contribute to inflammatory bone loss. This notion is consistent with the correlation between decreased periodontal expression of CD138 (a plasma cell marker) and decreased bone loss in anti-IL-17-treated LFA-1 KO mice. Our findings that LAD-I patients as well as both LFA-1 KO and CXCR2 KO mice share an IL-17-dominated periodontal disease phenotype suggest that an IL-17-driven mechanism for periodontal tissue destruction might be relevant to conditions other than LAD-I that are associated with poor or no accumulation of neutrophils in extravascular sites, owing to defective chemotaxis (for example, Chediak-Higashi syndrome and Papillon-Lefèvre syndrome) or neutropenic states (for example, congenital agranulocytosis, autoimmune neutropenia, HIV-associated neutropenia, and neutropenia in cancer patients under chemotherapy or radiation therapy). Similar to LAD-I individuals, patients with defective chemotaxis develop rapidly advancing inflammatory periodontal bone loss at a young age, and the same is observed in neutropenic patients unless their neutrophil count is appropriately corrected (7-10, 13, 25, 26, 40) .
Our studies also were aimed at characterizing the nature of the IL-17 response in LAD-I periodontitis and revealed that T cells were the primary source of IL-17, consistent with the recognition of T cellderived IL-17 in the pathogenesis of inflammatory bone loss in humans and animal models of arthritis (41, 42) . In mice, these cells were identified as CD3 + gd T cells, which, in the presence of IL-23, constitute an important source of IL-17 in murine mucosal tissues (43) 
CD8
− cells similar to the ones identified in patients with systemic lupus erythematosus or Sjögren's syndrome as dominant sources of pathogenic IL-17 (45, 46) . Our data support the hypothesis that the pathogenic role in LAD-I periodontitis of CD3 + IL-17-producing cells (whether T H 17 or gd T cells) is primarily related to their capacity to produce IL-17, a potent osteoclastogenic cytokine (42) . A secondary source of IL-17 in the mucosal setting of LAD-I periodontitis was CD3
-IL-17-producing cells. In LFA-1 KO mice, CD3 -IL-17-producing cells were further defined to be lineage-negative innate lymphoid cells, consistent with the capacity of IL-23 to up-regulate IL-17 in both adaptive and innate immune cells (47) . Innate lymphoid cells have recently emerged as innate cell populations with key barrier functions at mucosa sites (20) . Although the exact function of this cell population in the gingival tissue is not clear, our findings imply the possible association of innate lymphoid cells with an inflammatory disease state.
Our preclinical studies support the notion that neutralization of IL-17 (or IL-23) could effectively serve as an adjunctive therapy for generalized aggressive periodontitis associated with LAD-I and perhaps other LADs (for example, LAD-II, which involves defective glycosylation of selectin ligands) (10, 48) or conditions associated with poor or no recruitment of neutrophils (7-9, 13).
MATERIALS AND METHODS

Study design
The objective of this study was to understand the mechanism(s) underlying LAD-I periodontitis and identify candidate therapeutic targets. Research was performed under Institutional Review Board-approved protocols. Five LAD-I patients with defined CD18 mutations (table S1) and an equal number of control subjects were included in the studies, and their periodontal status was clinically evaluated. Oral tissues, fluids, dental plaque, and peripheral blood were obtained for gene expression analysis, immunohistological and microbiological studies, and flow cytometry of cell populations. The oral biopsies were performed either during therapeutic procedures or as elective research procedures.
Preclinical studies including intervention experiments with anti-IL-23 or anti-IL-17 were performed in LFA-1 KO mice, which exhibit the LAD-I periodontal phenotype. Animal experiments involved six mice per group (determined by GraphPad StatMate power analysis for a P value of 0.05 and a power of 0.80). All procedures described in this study were approved by the Institutional Animal Care and Use Committee, in compliance with established federal and state policies.
LAD diagnostics and clinical data
Patients were diagnosed with LAD-I on the basis of a defined CD18 mutation and flow cytometric analysis of CD18 expression on peripheral neutrophils, as previously described (49) . Neutrophil counts were extracted from routine patients' complete blood counts.
Clinical examination and determination of bone loss in humans Loss of tooth-supporting connective tissue and bone (CAL) was clinically measured, with a periodontal probe calibrated in millimeters, at six sites per tooth in all teeth per patient and expressed as mean measurement per patient. Periodontal disease diagnosis was performed according to the criteria of the American Academy of Periodontology (50), with sites exhibiting CAL >5 mm considered to be severe periodontitis.
Human tissue specimens
Periodontitis-involved tissue samples from patients diagnosed with severe chronic periodontitis or LAD-I periodontitis were obtained during therapeutic surgery. Inclusion criteria for diseased tissues were evidence of inflammation (bleeding on probing) and advanced loss of tooth-supporting structures (CAL >5 mm). Inflamed tissues without associated bone loss (that is, gingivitis) and healthy tissue (noninflamed) samples were obtained as oral biopsies. Research involving human subjects was reviewed and approved by the Institutional Review Boards of National Institutes of Health (NIH). All patients provided written informed consent for participation. Tissues were either immediately placed in zinc-formalin (Anatech) for histology, snapfrozen for RNA studies, or placed in RPMI medium (Invitrogen) for flow cytometry.
Immunohistochemistry Formalin-fixed tissues were embedded in paraffin and sectioned into 5-mm sections, deparaffinized, and rehydrated, followed by heat-induced epitope retrieval. Methanol containing 3% H 2 O 2 was used to block the endogenous peroxidase for 15 to 30 min. Sections were then blocked with bovine serum albumin and incubated for 1 hour at room temperature or overnight at 4°C with primary antibody to CD3, CD138, CD68, DC-SIGN (Abcam), IL-17A (R&D Systems), mast cell tryptase (Dako), CD15 (Novus), CD56 (Thermo Scientific), TCRgd (eBioscience), or isotype controls. After washing with phosphate-buffered saline three times, immunolabeling was performed with the ImmPRESS detection system (Vector) followed by visualization with ImmPACT DAB peroxidase substrate. Finally, the specimens were counterstained with Mayer's hematoxylin and mounted with Permount (Fisher), and sections were scanned with a ScanScope (Aperio).
Cell isolation from gingiva and flow cytometry All human or mouse tissue samples were digested in a collagenase (Invitrogen) and deoxyribonuclease (Sigma) mix for 1 hour at 37°C with agitation. A single-cell suspension was then generated by mashing digested samples through a 70-mm filter (BD Biosciences). Single-cell suspensions from gingival tissues, or human PBMCs, were stimulated for 3.5 hours with or without PMA (50 ng/ml; Sigma) and ionomycin (2.5 mg/ml; Sigma) in the presence of brefeldin A. At the end of the incubation period, human cells were stained with Live/Dead Cell Viability assay (Invitrogen) and anti-human CD3, CD14 (BioLegend), CD45, CD4, CD8, TCRgd, CD161, CD56, CD19, CD117, CD127, and IL-17A (eBioscience). Mouse cells were stained with Viability stain (Zombie Yellow, BioLegend) and antibodies to CD45, TCRab, TCRgd, CD4, NK1.1, CD3, CD5, CD11b, CD11c, CD19, CD90, CD117 (eBioscience), Ly6G (BD Bioscience), and IL-17 (BioLegend). All samples were analyzed with a FACS Fortessa cytometer (BD Biosciences). Data analysis was performed with FlowJo software (Tree Star).
Cytokine protein measurements
Humans. Cytokines were measured in human blood plasma and gingival crevicular fluid with a custom-designed Panomics Procarta Cytokine Profiling Assay, on the basis of Luminex technology (Affymetrix).
Mice. Gingival tissue was excised from around the maxillary molars and homogenized as previously described (51) . Cytokine levels were determined in soluble extracts by enzyme-linked immunosorbent assay with commercially available kits (eBioscience). Cytokine protein concentrations were normalized to the total protein concentrations in the tissue homogenates, as measured with the Coomassie Plus (Bradford) protein assay kit (Pierce). ).
Cytokine mRNA expression in periodontal tissues
Bacteria quantification
Human samples. Bacterial DNA was extracted from human toothassociated subgingival biofilm (dental plaque) samples and from 5-mm-thick gingival tissue sections with the MasterAmp DNA Extraction Kit (Epicentre Biotechnologies). Total bacterial load was determined via real-time PCR with 16S universal primers (52) .
Mouse samples. Genomic DNA isolated from maxillary palatal and buccal gingiva and hard tissue (teeth and immediately surrounding bone) was used to determine total bacterial counts by quantitative real-time PCR of the 16S rRNA gene (19, 53) . Bacterial samples from mouse oral cavities were also obtained with sterile fine-tipped cotton swabs held against the gum line for 30 s. Serial dilutions of the swab extracts were plated onto blood agar plates for anaerobic growth and determination of colony-forming units.
Mice and determination of periodontal bone loss LFA-1 KO mice on a C57BL/6 background were provided by C. M. Ballantyne (Baylor College of Medicine) (15) . CXCR2 KO mice on C57BL/6 background and wild-type C57BL/6 controls were obtained from The Jackson Laboratory. Periodontal bone heights were assessed in defleshed maxillae under a dissecting microscope (objective, 40×) fitted with a video image marker measurement system (VIA-170K; Boeckeler Instruments). The distance between the CEJ and the ABC was measured at 14 predetermined maxillary sites (54) . For calculation of relative bone loss (for example, LFA-1 KO mice versus wild-type controls), the 14-site total CEJ-ABC distance for each mouse was subtracted from the mean CEJ-ABC distance of control mice. The results are presented in millimeters; negative values indicate bone loss relative to controls.
Intervention experiments in mice
A neutralizing mAb to IL-17A (rat IgG2a; M210) was provided by Amgen, and azide-free rat IgG2a (RTK2758; BioLegend) served as isotype control. Purified polyclonal goat IgG antibody to IL-23p19 subunit and nonimmune IgG control were purchased from R&D Systems. The antibodies or their controls were microinjected locally into the murine palatal gingiva (5 mg per site), three times weekly, with a 28.5-gauge Micro-Fine needle (BD Biosciences). Microinjections were performed on the mesial of the first molar and in the papillae between first and second and third molars on both sides of the maxilla (19) .
Statistical analysis
Data were evaluated with one-way ANOVA and the Dunnett multiplecomparison test with the InStat program (GraphPad Software). Where appropriate (comparison of two groups only), two-tailed t tests were performed. P values <0.05 were considered to be statistically significant.
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